Objectives: Average 2-year survival after cardiac transplantation is approximately 80%. The evolution and subsequent approval of larger pulsatile and, more recently, continuous flow mechanical circulatory support (MCS) technology for destination therapy (DT) offers the potential for triage of some patients awaiting cardiac transplantation to DT. Results: By multivariable analysis, risk factors (P<.05) for mortality after DT included older age, larger body mass index, history of cancer, history of cardiac surgery, INTERMACS level I (cardiogenic shock), dialysis, increased blood urea nitrogen, use of a pulsatile flow device, and use of a right ventricular assist device (RVAD). Among patients with a continuous flow LVAD who were not in cardiogenic shock, a particularly favorable survival was associated with no cancer, patients not in cardiogenic shock, and blood urea nitrogen less than 50 mg/dL, resulting in 1-and 2-year survivals of 88% and 80%.
Durable mechanical circulatory support (MCS) systems have evolved into therapies suitable for multiyear support. In the United States, the historical development of such support devices was linked to cardiac transplantation, addressing the universal shortage of suitable donors for cardiac transplantation. The vast majority of durable devices have been implanted as bridge-to-transplant therapy, with a small subset implanted as a bridge-to-ventricular recovery. When MCS therapy in the United States was expanded to include the intent of long-term ''destination'' therapy (DT) in 2003, 1 Medicare and most other providers considered DT appropriate only for patients not considered eligible for cardiac transplantation, based on inferior demonstrated survival with MCS compared with transplantation.
However, the landscape of devices, their expected durability, and patient outcomes have rapidly evolved over the past 4 years. This study was undertaken to examine, through a national MCS database, the hypothesis that ''mechanical circulatory support as DT has evolved to a level that justifies consideration of selected patients for DT who are transplant eligible.''
MATERIALS AND METHODS Interagency Registry for Mechanically Assisted Circulatory Support Database
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) is a registry for durable (suitable for patient discharge) MCS devices approved by the US Food and Drug Administration (FDA) and implanted in the United States. The registry is sponsored by the National Heart, Lung, and Blood Institute (NHLBI). The term ''interagency'' emphasizes the unique collaboration between the NHLBI as the funding and scientific support agency, the FDA as the regulatory agency, and the Center for Medicaid and Medicare Services (CMS) as the federal reimbursement agency. 2 Information collected in the INTERMACS database includes patient profile data, implant and device data, scheduled follow-up information, and event-driven data. The occurrence of infection, device failure, neurologic events, and death trigger the acquisition of additional relevant data elements. Participation in INTERMACS is a requirement for hospitals to be reimbursed by CMS for the implantation of MCS devices intended for permanent or ''destination'' therapy (DT 
Study Group
Of these 5614 registry patients, 1287 patients received a VAD as DT ( Figure 1 ). These 1287 patients are the subject of this analysis. The study inclusion criteria are listed in Table 1 . At the time of implant, 1256 patients received a left VAD (LVAD) only, and 31 received biventricular support. In the overall experience, 127 DT implants were pulsatile devices and 1160 were continuous flow pumps (see again Figure 1 ).
Missing DT Patients From INTERMACS
Patients receiving MCS implants in the United States who are entered into INTERMACS must fulfill 2 criteria: (1) the device implanted must be FDA approved and (2) the patient must provide informed consent for entry of his or her data into INTERMACS. For FDA-approved devices, INTERMACS receives data on device implant and survival/mortality at 48 hours for all patients, even if consent is not obtained. Further followup is available only if patient consent is obtained. INTERMACS audits and screening logs indicate that 9.6% of patients suitable for INTERMACS were not entered with full data collection owing to failure to obtain informed consent. INTERMACS receives no information for patients who receive an investigational device as part of a clinical trial.
Follow-up
All patients are followed up as part of the requirements of INTERMACS until 1 of 3 end points is reached: death, transplant, or device explant for recovery. Data collection at routine follow-up intervals (see Appendix  Table 1 ) occurs for a variety of routine clinical variables in addition to data forms that are ''triggered'' by specific adverse events. Among the 1287 DT patients, follow-up was available in greater than 99% at the follow-up date of December 31, 2011.
Adverse Event Definitions
Standardized definitions for adverse events were established during the initial phase of INTERMACS, developed with the participation and agreement of experts in the field, FDA, and industry. The adverse event definitions are included in Appendix Table 2 .
INTERMACS Profiles
The INTERMACS profiles represent a reclassification of New York Heart Association (NYHA) class IV heart failure. 3 The profiles are listed in Appendix Table 3 .
Statistical Methods
Standard Kaplan-Meier actuarial methods as well as parametric depictions were used to examine survival and freedom from other specific events. Standard methods were used to examine whether differences among variables were likely due to chance. Competing outcomes depictions used standard methodology as described by McGiffin and colleagues. 4 Appendix Table 4 . The risk factor equations are listed in Appendix Table 5 .
Transplant Survival
Expected survival after cardiac transplantation was drawn from the registry of the International Society for Heart and Lung Transplantation. 5 
Quality of Life Studies
All institutions were encouraged to apply quality of life instruments to patients receiving MCS, beginning before implantation and repeated at specified intervals thereafter. The selected quality of life instruments included the EuroQol (EQ)-5D and the EQ visual analog scale score. The EQ-5D is a standardized instrument designed as a measure of health outcome and applicable to a wide range of health conditions and treatments. This test is primarily designed for self-completion by the respondents, examining the dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ visual analog scale instrument includes a standard vertical 20-cm visual analog scale (similar to a thermometer) for recording an individual's self-rating regarding his or her personal general health-related quality of life state.
RESULTS

Evolution of DT
During the early phase of INTERMACS, continuous flow technology was not yet FDA approved for adult patients. During the era in which essentially only pulsatile pumps were entered into INTERMACS (June 2006-December 2007), only 13% of pumps were implanted with a strategy of DT. With the approval of the HeartMate II continuous flow device (Thoratec Corporation, Pleasanton, Calif) for DT in January 2010, the number and proportion of pumps implanted as DT progressively increased (Table  2) . During the year 2011, 96% of primary device implants (for any strategy) were continuous flow pumps ( Figure 2 ). DT accounted for 38% of implants during 2011, and all DT patients received continuous flow devices ( Figure 3 ).
Reasons for Transplant Ineligibility
A variety of contraindications to transplants were cited, some of which were absolute while others were potentially reversible during VAD support (Table 3 ). The most frequently cited contraindication was advanced age (38% of patients), followed by renal dysfunction (20%), high body mass index (14%), and pulmonary hypertension (12%). Approximately 35% were considered potentially modifiable, indicating the possibility of later suitability for transplantation.
Outcome of Patients With Initial DT Strategy
As noted in the previous section, many of the contraindications to transplantation at the time of device implant were considered potentially reversible. As their clinical situation evolved over time, some patients were reconsidered for cardiac transplantation, or, potentially, for device explant. These events are tracked by the competing outcomes depictions in Figure 4 for pulsatile devices and Figure 5 for continuous flow devices. In the current era of continuous flow DT devices, less than 5% of patients undergo transplantation or explant within 2 years.
Adverse Events
Infection and bleeding were the most common adverse events, followed by respiratory failure, neurologic events, and renal dysfunction (Table 4) . Of note, the adverse event profile differed between pulsatile and continuous flow pumps (Table 4) . Device malfunction, bleeding, infection, stroke, renal dysfunction, and respiratory failure all occurred with a significantly higher event rate with pulsatile pumps.
Device malfunction severe enough to require pump exchange or cause death was strikingly different between pump types ( Figure 6 ). The hazard function (instantaneous risk) for device failure progressively increased over the 2 years of follow-up for pulsatile pumps, whereas the hazard function for continuous flow devices Primary Implant Enrollment, Destination Therapy: n=1287 FIGURE 3 . Destination therapy device implants by year, stratified by device type. Cont, Continuous flow; Intra, intracorporeal; Puls, pulsatile.
remained low and essentially constant. For pulsatile pumps, the freedom from device exchange was only 51% at 24 months, compared with 94% for continuous flow pumps.
Survival
The overall actuarial survival among all DT patients was 75% at 1 year and 62% at 2 years ( Figure 7 ). The hazard function shows a rapidly falling early phase that merges with a constant phase at about 3 months.
Cause of Death
The primary causes of death differed according to time interval after implant as well as device type (Tables 5 and  6 ). Cardiac failure was the major cause of early mortality, and 32% of those patients received their device while in cardiogenic shock. No other specific cause of death was predominantly related to either device type or interval from implant to death.
Risk Factors for Mortality
Risk factors for mortality in the early and constant phases identified by multivariable analysis are listed in Table 7 . Older age. The hazard ratio of 1.24 reflects the increase in risk from age 60 to 70 years. Perhaps not surprising is the finding that elderly patients receiving DT had a lower general risk profile than did younger patients. Without risk adjustment, the actuarial survival for older and younger patients was similar (Figure 8 ). INTERMACS level 1. INTERMACS level 1 identifies those patients in cardiogenic shock at the time of VAD implant (see Appendix Table 3 ). The progressive decrease in Figure 4 . the proportion of patients in level 1 at implant over the course of the study is documented in Table 8 . The inferior survival when DT was undertaken in the face of cardiogenic shock is apparent in Figure 9 .
Severe right ventricular failure. Right ventricular failure sufficient to require support with a biventricular assist device at the time of implant was the strongest predictor of mortality in the constant phase (see again Table 7 ). The need for biventricular support resulted in a marked reduction in survival for both pulsatile and continuous flow LVADs ( Figure 10 ). The likelihood of right VAD (RVAD) implant at the time of DT was 5.5% for pulsatile LVADS but fell to 2.1% with continuous flow technology. Among the 48 RVAD implants, 31 (65%) occurred at the time of LVAD implant, 2 (4%) later the same day, 9 (19%) between 0 and 7 days, and 6 (12%) more than 7 days after LVAD ( Figure 11 ). RVAD explant occurred in 9 (19%) of 48 patients receiving an RVAD. The duration of RVAD support ranged from 2 to 37 days (mean, 18). The likelihood of needing biventricular support was Hazard ratio, The rate for pulsatile pump divided by the rate for continuous flow pump. CNS, Central nervous system. *With current reporting, identification of hypertension with continuous flow pumps is unreliable. 3 times as high for patients in level 1 compared with levels 3 to 7.
Pulsatile pump technology. In this experience, the use of a pulsatile pump yielded inferior survival compared with a current continuous flow device (Figure 12 ), in which the 1-and 2-year actuarial survivals were 76% and 67%. In general, pulsatile pump patients were slightly older and had somewhat worse renal and hepatic function than did continuous flow patients ( Table 9 ).
Quality of Life
On the basis of the EQ-5D quality of life instruments, patients receiving a continuous flow pump as DT noted a significant reduction (P < .05) in both some and extreme problems with mobility, self-care ( Figure 13 ), usual activities of living (Figure 14) , and anxiety/depression, comparing before implant with 3, 6, and 12 months after implant. In the area of pain and discomfort, significantly fewer patients noted this symptom complex after implant, but 6% of patients interviewed continued to have extreme symptoms of pain and discomfort up to 1 year after LVAD implant. The EQ-5D visual analog scale (see details under Material and Methods) demonstrated prompt improvement within 3 months after VAD implant, which was maintained during the first year after implant ( Figure 15 ).
Current Expected Survival After Cardiac Transplantation
The current average survival after cardiac transplantation, as a benchmark for comparing posttransplant survival against DT, is derived from the most recent International Society for Heart and Lung Transplant Registry. 5 The average 2-year risk-unadjusted survival in the most recent cohort is approximately 80% (Figure 16 ).
Survival Justification for Potential Triage From Transplant to DT Therapy
If we use the non-risk-adjusted 2-year transplant survival of 80% as an initial survival metric, generating solutions to the multivariate equation provides insight into patient subsets who would likely achieve the level of 2-year survival that might begin to compete with transplantation. Figure 17 depicts the age effect for a stable (INTERMACS level 3 or greater) patient with preserved renal function and without severe right ventricular failure who receives a continuous flow pump, stratified by the presence or absence of prior cardiac operations. For the patient with prior cardiac surgery, the 70% confidence limits overlap with a survival of at least 80% at 2 years for patients less than about 40 years of age; but for the patient without prior cardiac surgery, survival is likely to be at least 80% at 2 years for patients aged 62 years or less. Figure 18 displays the solution to the multivariable equation for a 60-year-old patient with preserved renal function and without right ventricular failure who receives a continuous flow pump, depicted for various body mass indexes stratified by the presence or absence of prior cardiac surgery. Overall, about 20% of the DT population experienced 2-year survival equal to or greater than the transplant reference line of 80% ( Figure 19 ).
DISCUSSION
Evolution of DT
As early as 1991, the Institute of Medicine recognized the importance of detailed longitudinal follow-up data on During the first 2 years of the INTERMACS experience, the landscape of approved device therapy was dominated by pulsatile technology, inasmuch as continuous flow pumps were largely still under investigation in clinical trials. 8 With the general recognition that the HeartMate XVE device was prone to device malfunction with the frequent need for reoperation within 12 to 18 months (see again Figure 6 ), few such pumps were being implanted for DT. With escalating enthusiasm for continuous flow technology in Europe and the United States, many patients poorly suited for cardiac transplantation received a continuous flow pump (approved for bridge-totransplant therapy in 2008) under the reimbursable approved indication of bridge to transplant. 9 In reality, the transplant status of this group of patients was ambiguous, and MCS therapy was often applied as a strategy of ''bridge to candidacy.'' 9 Predictably, VADs implanted as DT represented less than 10% of devices entered into IN-TERMACS between 2006 and 2009. 10 The marked increase in pumps implanted as DT in 2010 and 2011 (more than 30% of total implants) 8 coincided with the approval of the HeartMate II continuous flow pump for DT in January of 2010.
This rapid evolution toward continuous flow technology is poignantly reflected in the INTERMACS registry during the most recent era (see again Figure 2 ). Greater than 95% of devices entered into INTERMACS in 2010 and 2011 were continuous flow pumps, and all DT devices were continuous flow devices. 9 The general enthusiasm for continuous flow devices in DT strategies was also supported by the multi-institutional study of Park and colleagues. 11 
Reasons for Transplant Ineligibility
Despite the intended strategy of DT as a ''permanent'' therapy for advanced heart failure, the clinical reality is that few therapies are exclusively ''either/or'' for the . Percent of patients with some or extreme problems with usual activities before and at intervals after destination therapy with a continuous flow pump. The depiction and abbreviations are as in Figure 13 . CF, Continuous flow; LVAD, left ventricular assist device. duration of the heart failure patient's life. Even with the most successful MCS, patients will be followed up indefinitely with scheduled reevaluations to determine whether the device, heart transplantation, explant, or potentially other therapies provide the greatest opportunity going forward for the highest quality extended survival. The appreciation of possible neutralization of certain transplant contraindications after device implant was previously addressed by Kirklin and colleagues 10 in categorizing such contraindications as ''modifiable'' or ''un-modifiable.'' The challenge of clinical prescience regarding the reversibility of many comorbid conditions is embodied in the designation ''bridge to candidacy,'' which is currently the most common device strategy (not an FDA-approved indication) among implant recipients 9 in INTERMACS.
Outcome of Patients With Initial DT Strategy
Despite the potential impurity of the designation DT as well as likely overlap (in terms of actually pursuing a course of long-term VAD therapy) with other strategy designations such as ''bridge to candidacy,'' this study was well suited to critically analyze patients who received extended support with durable devices. Other studies have made inferences about ''long-term'' device therapy from patient populations 8, 12, 13 ultimately committed to transplantation. The ''censoring'' of patients at time of transplant introduces considerable uncertainty about long-term device potential, in that patients with major device complications (which would likely affect patient survival and quality of life if the device was retained) often undergo transplantation at an increased priority level, thereby potentially avoiding an unfavorable VAD outcome. This study had relatively few such patients, in that only about 10% of pulsatile device patients underwent transplantation during the study period, and less than 5% of continuous flow patients (see again Figures 4 and 5) were diverted to transplant.
Adverse Events
In the evaluation of patients potentially suitable for either cardiac transplantation or MCS DT, the expected life satisfaction during extended support will ultimately exert a major influence on therapy selection for both practitioner and patient. In this sense, therapy comparison and selection is confounded by the striking differences in the adverse event profiles of heart transplantation versus MCS. Whereas transplantation is challenged by the complications of rejection, infection, malignancy, and allograft vasculopathy, Table  5 ). The nomograms are generated with variables set as indicated for 2 patients according to body mass index. Depiction is as in Figure 17 . the adverse event profile of the MCS patient is dominated by device-related infection, bleeding events, right heart failure, central nervous system events, and device malfunction. 9, 10, 15 The concept of adverse event burden 8 (see again  Table 4 ) might provide a unifying method of expressing the overall adverse event impact of each therapy, but ultimately the patient will need to participate in therapy selection based, in part, on a subjective analysis of the relevant adverse event profile and how that might affect life satisfaction.
Survival
The pace of progress in effective extended MCS has been well chronicled since the original REMATCH publication cited a 2-year survival less than 25% with the HeartMate XVE as DT. 7 Subsequent reports with the same pump technology reported 2-year survival of nearly 60%.
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With continuous flow technology as bridge-to-transplant therapy, 1-year survival improved from 68% in the original HeartMate II bridge-to-transplant trial 12 to 73% in the midtrial update. 11 In the subsequent HeartMate II DT trial, 2-year survival improved from 58% in the early trial experience to 63% for the midtrial group. 11 The clear survival benefit of continuous flow technology over pulsatile pumps for DT was documented in the INTERMACS analysis of 2011. 10 Other studies indicate that survival improvements have continued despite little change in overall patient risk profile over the past 4 years. 9 The trajectory of incremental survival documented in this analysis is consistent with improvements in the field of MCS over the past 5 to 8 years.
Risk Factors for DT
The NYHA class IV designation has become the major descriptor of heart failure level sufficiently severe to warrant device therapy or transplantation, but it is widely recognized that this encompasses different levels of clinical decompensation. The current analysis identified patients in cardiogenic shock to be at higher risk for mortality with DT, a finding noted early in the INTERMACS experience. 8 This finding was facilitated by the INTERMACS subclassification of NYHA class IV for heart failure, in which 5 INTERMACS profiles describe the various stages of NYHA class IV (see again Appendix Table 3 ). After the first year of data collection, over 40% of patients receiving durable devices were in acute decompensation (level 1, cardiogenic shock). With the appreciation of the important increment of mortality associated with implantation under such unstable conditions, the proportion of patients receiving implants in shock fell to under 15% in 2010. 9 Currently, increasing proportions of patients are currently implanted in the lower INTERMACS levels of NYHA class IV.
Right ventricular dysfunction severe enough to require RVAD support was the greatest predictor of subsequent mortality, which has been a consistent finding in prior INTERMACS analyses. 2, 8, 9, 10 Precise definitions of various degrees of right ventricular dysfunction have proved challenging and have been recently modified to better reflect clinical correlates (see Appendix Table 2 ). Even the identification of severe right ventricular failure by the need for RVAD support is rather subjective, inasmuch as the specific trigger for initiating RVAD placement differs among experienced VAD surgeons. The importance of identifying patients at risk for severe right ventricular failure is evident, inasmuch as such patients on the transplant list would be poor candidates for triage to DT VAD therapy. INTERMACS has viewed right ventricular dysfunction to be such a critical issue that a scientific task force is being assembled to address the issues of identification, prevention, and management of the failing right ventricle during LVAD support.
Quality of Life
The findings of improved quality-of-life indicators as judged by the EQ-5D instrument are consistent with improvements in quality of life and functional status using the Minnesota Living with Heart Failure Questionnaire. 16, 17 and the Kansas City Cardiomyopathy Questionnaire 18 in the HeartMate II device trial. 19, 20 Other studies have shown substantial improvement in the 6-minute walk test after implant. 20 Similar positive findings were reported by Park and colleagues. 11 Although a myriad of studies have documented improvement in quality of life and functional outcome indicators after heart transplantation, 21, 22 few studies have directly compared transplantation with MCS. 23 
Survival Justification to Triage From Transplant to DT Therapy
The solutions to the risk factor model provide insight into the types of patients who, depending on their comorbidities for cardiac transplantation, might warrant consideration for triage to DT MCS with continuous flow technology. The profile of such patients would currently include preserved renal function, absence of severe right ventricular failure, stable cardiovascular function on inotropic support, and body mass index suitable for transplant. Currently, the model does not justify triage to DT if the patient has undergone previous cardiac operations except for relatively young patients, a group less likely to select long-term pump support unless they were highly sensitized. Although this model would not yet support tapping into the large cohort of patients with prior cardiac operations, details of that decision-making process would depend on risk factor modeling within the transplant population to seek subsets whose predicted 2-year survival might be less than 80%. Realizing that inferences are being drawn from a group of patients considered ineligible for cardiac transplantation, the stratified actuarial depiction in Figure 19 suggests that nearly 20% of the actual DT patient population achieved survival that would be competitive with the ''average'' transplant patient.
If such triage decisions did occur, a paradigm shift of this magnitude in the arena of advanced heart failure would certainly accelerate the pace of device implants and potentially affect listing criteria at major heart transplant centers as well as allocation algorithms. Major challenges to ensure truly informed patient decisions regarding device therapy versus transplantation would further confound decisions in this evolving platform of heart failure care.
Of course, the primary metric would be survival, but survival at what interval? Is predicted 2-year survival of sufficient duration for such a paradigm shift? In great measure the answer depends on the ''expected'' trajectory of the survival curve beyond 2 years, inasmuch as the possibility appears remote that patients and providers will await 5 more years of patient follow-up, a randomized trial of VAD versus transplant, or other longitudinal analyses before beginning the ''shift.'' Societal and health care ''impatience'' is already evident with the ''REVIVE IT'' trial, which allocates long-term device therapy possibly before the patient would normally be considered for transplantation.
Another imponderable in this therapeutic allocation process is the clear knowledge that the patients with a DT device can always be reconsidered for cardiac transplantation if device complications or other impairments in quality of life tip the balance toward transplantation. Other unintended consequences may occur: the whole priority allocation for other patients awaiting transplantation may be affected, and hospitals without expertise in transplant surgery and medicine may preferentially (and possibly inappropriately) offer devices rather than transplant to transplant-eligible patients.
Once this ''magic metric'' of survival (eg, 80% at 2 years) is accepted for devices in the advanced heart failure community, other metrics that majorly affect the quality of patient existence will assume center stage in our ongoing analyses. For just that reason, quality of life and functional outcome indicators represent a major INTERMACS focus in future analyses.
In considering specific patients for triage from transplantation to device therapy, the presence of noncardiac comorbidities is known to impair long-term survival after cardiac transplantation, as has been quantified in an analysis from the Cardiac Research Database. 24 Another important group of patients for potential triage are those who are highly sensitized with circulating anti-HLA antibodies. The opportunity for DT could provide an important benefit for these sensitized patients who frequently endure long waiting times while continuing to experience symptoms of advanced heart failure. Ultimately, the triage of these higher risk transplant subsets could increase the survival utility of the precious and limited resource of donor hearts.
Study Limitations
Inferences from this database have important strengths and weaknesses. The strengths include the scope and rigor of INTERMACS. As an NHLBI initiative, INTERMACS engages National Institutes of Health oversight, follows Observational Study Monitoring Board surveillance, and requires performance standards of participating institutions. The power of INTERMACS is further enhanced by the CMS mandate for data submission on all approved and consented durable MCS devices implanted at centers approved for DT therapy, formal definitions and processes for adjudication of adverse events, dedicated electronic data submission, compulsive data monitoring, and a hospital auditing process, all of which raise INTERMACS close to the rigor of a clinical trial. Indeed, the quality and completeness of data collection have been of sufficient quality that the FDA has embraced the use of INTERMACS patients as ''concurrent controls'' in at least 1 pivotal clinical device trial, 25 and the INTERMACS platform has been held in high regard by the NHLBI. 1 However, important study limitations relate to the knowledge that INTERMACS does not represent a complete sample of DT patients. Follow-up is not available for patients who do not provide informed consent, which represents about 9.6% of available patients with FDA-approved devices. One could speculate about whether these patients represent a higher risk group. Furthermore, all patients who receive DT therapy as part of a clinical device trial are excluded from INTERMACS. Finally, maximal follow-up of continuous flow DT patients is only now exceeding 2 years, generating uncertainty about truly longterm survival.
CONCLUSIONS
1. DT represents an increasing LVAD application and currently accounts for nearly one third of overall MCS activity in the United States. 2. Evolution from pulsatile to continuous flow technology has dramatically improved 1-and 2-year survivals. 3. DT is not appropriate for patients with rapid hemodynamic deterioration or cardiogenic shock. 4. The presence of severe right ventricular failure is a contraindication for DT. 5. Important subsets of DT patients now enjoy survival that may be competitive with heart transplantation out to about 2 years. 6. Future studies will focus on transplant-eligible subsets who may benefit from informed discussions about MCS as an alternative long-term option.
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Discussion
Dr Soon J. Park (Rochester, Minn). Dr Kirklin and his colleagues are to be congratulated for this timely and important presentation. They report that a significant fraction of DT patients are achieving a survival that is comparable with that of those who undergo heart transplantation. Such finding is especially astonishing in that these patients, by definition, were those deemed inappropriate to allocate donor hearts for the concern of poor posttransplant outcome.
Perhaps it is helpful to revisit the medical ethics governing heart transplantation, which was established well before the current development in LVAD therapy. Heart transplantation has been the only therapeutic option capable of prolonging life in these patients with end-stage heart failure. Although it is highly effective on an individual level, its epidemiologic impact has been trivial for there exists a significant mismatch between donors and recipients. The donor heart remains a precious and scarce resource for society. Therefore, the practice of heart transplantation has been guided by principles of justice, utility, and transplant benefit to maximize the number of years gained by the transplantation.
With the recent development in LVAD therapy, heart transplant no longer seems to be the only viable option. Now, LVAD therapy can be rendered immediately and abundantly, and it is going to change the natural history of patients with end-stage heart failure dramatically, whether transplant eligible or not.
As we have just been informed by Dr Kirklin, a significant fraction of patients who were destined to die because heart transplant was not an option, a typical scenario of despair that affects the vast majority of patients, are now able to enjoy life on LVAD support.
In regard to the transplant-eligible patients, many medical centers seem to witness a significantly enhanced rate of survival in these bridge-to-transplant patients compared with DT patients. What is the INTERMACS bridge-to-transplant experience? How does it compare with the attrition rate of 4% due to various causes such as rejection, infection, allograft vasculopathy, and malignancy after transplantation? What would be the appropriate LVAD strategy in terms of patient selection, duration of support, and timing of triggering transplantation in accordance with the principles of transplantation? Finally, would it ever make sense to consider LVAD as the primary therapy and reserve heart transplantation as a secondary therapy? I would welcome Dr Kirklin's insight into some of these questions, and, once again, congratulations for ushering in a truly exciting period of LVAD therapy.
Dr Kirklin. Thank you, Dr Park. Those are interesting questions.
You asked about the mortality or attrition rate with cardiac transplantation versus ventricular support. In the INTERMACS database, recall that the continuous flow technology is really now only exceeding 2 years, and during that time in the low-risk group, the mortality rate is about 10% per year, which compares with about 6% per year in the constant phase after cardiac transplantation. Thus it is not quite there yet, even though there are specific risk factor groups that are competitive out to 2 years. Of course, the mechanical support group includes older patients; the median age in the INTERMACS DT group was 67 years versus 55 years in the transplant group.
Regarding the issue of using LVAD therapy as primary therapy and transplantation secondary, of course, the goal in the future will be to have an array of therapies that maximizes long-term survival for patients. Whether that means initial VAD therapy followed by transplant or initial transplant followed by a total artificial heart will depend on the kinds of rigorous analyses that we will need to do in the future. There is going to be the requirement for rigorous transplant databases to get risk-appropriate patients as well as ongoing analyses of these mechanical support databases.
Dr John V. Conte (Baltimore, Md). Dr Kirklin, congratulations on a very thought-provoking paper. Having heard you say about 2 years ago that mechanical support would not be equivalent of heart transplantation at this point in time, it is refreshing to hear that you have somewhat changed your tone based on these data. Are you ready right now to refer this subset of patients for mechanical support rather than transplantation? If not, what duration of long-term follow-up would you consider necessary before you would refer that subset of patients you just presented?
Finally, is there a financial consideration in referring this subgroup of patients for long-term therapy? What role do the economics of transplantation and mechanical support play in this decision?
Dr Kirklin. The actual identification of patients on the transplant list who could be triaged to mechanical support will depend, of course, on their comorbidities, and there are analyses available from previous experiences that would allow us to begin that triage effort. Currently, however, it is going to be challenging, because there is more contemporary data about risk stratification in MCS patients, ironically, than there is in the current era of cardiac transplantation. It is appropriate to begin triaging certain patients-those with multiple comorbidities who are likely to have a long wait for cardiac transplantation, such as sensitized patients.
The financial implications are complicated and will have to be determined by societal as well as medical priorities. Clearly, we are going to be looking at the financial implications over decades of patient care if we are going to be using a combination of mechanical support, transplantation, and potentially other therapies.
Dr Conte. To answer the question directly, are you ready as you stand there today to refer that subgroup of patients for DT as opposed to transplantation? I am going to hang you on your words. Dr Kirklin. Yes. Dr R. Duane Davis (Durham, NC). Congratulations. I just want to be a little bit cautious when you use that 20% 2-year survival in heart transplant as your benchmark and then compare a 40-yearold who has never had surgery getting a VAD and saying it is equivalent. If you did a 40-year-old who never had previous cardiac surgery, the 2-year mortality would not be 20% after a heart transplant. It is clear that continuous VAD is getting into the ballpark, but I am not sure I am ready to agree that it is equivalent.
Finally, when are we going to be ready to randomize between those 2 therapies?
Dr Kirklin. The challenge in transplantation is to begin to set some benchmark about which we could begin to have this discussion, and I think a benchmark of 20% mortality at 2 years is certainly reasonable. Remember that the low-risk, 40-year-old patient undergoing cardiac transplantation without important other comorbidities is not the patient one would want to triage to mechanical support. The reason this benchmark is important is to begin the discussion of those kinds of patients who could potentially be triaged if they are a low enough risk with device therapy. However, it will only be those patients who are on the transplant list with multiple adverse comorbidities that we are going to initially select for triage. It will not be the otherwise healthy 40-year-old man with a good long-term expectation from cardiac transplantation.
Dr Joseph Amato (Chicago, Ill). Dr Kirklin, Dr Pagani, I congratulate you on your work. Last week, I was at the FDA meeting in regard to the INTERMACS pump. I witnessed the pump in action, and all the other committee members there approved this dynamic pump. I disagree with the comments made in regard to the continued improvement in searching for a bridge to transplant and that the impact as mentioned is trivial. The experience in Europe has been highly successful and we await a smaller version. It is a compact and beautiful little pump. 
